Bayer Confident CureVac COVID Pact Will Be A Success
Plans To Deliver mRNA Vaccine On Track
Executive Summary
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
You may also be interested in...
Novartis Teams Up With CureVac To Make COVID-19 Vaccine
The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.
Merck & Co. Pushes Back On Modest Projections For Verquvo
Merck & Co.'s vericiguat, an sGC stimulator, was approved for heart failure but it enters a competitive space with a narrow indication.
CureVac Enlists Bayer To Secure Place Among COVID-19 Vaccines ‘Second Wave’
While demand for COVID-19 vaccines will be huge for the next two years, only those players with major manufacturing and commercial infrastructures in place will play a big role.